Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Cancer Res. 2018 May 29;78(15):4360–4369. doi: 10.1158/0008-5472.CAN-17-3124

Figure 5. In vivo efficacy of combined CDK4/6 and c-Met/Trk inhibition.

Figure 5

(A–B) Kaplan-Meier survival curves of mouse xenografts with two different treatment regimens. G88 or G528 GICs were stereotactically injected into the brains of mice. Mice were randomized into 4 groups: control, altiratinib only, abemaciclib only, and the combined treatment. The efficacy of the combined treatment in each regimen is comparable to each other and significantly higher than the individual treatments (*P < 0.05; n = 8 mice per cohort). (C) Comparison of mouse body weight in each treatment group. (D–E) In vivo modification of the targets of both abemaciclib and altiratinib. Shown are immunoblots using antibodies specific for c-Met, Trk, p-Rb, and Cyclin A. Protein expressions were quantitated and plotted (*P < 0.05; ***P < 0.001; one-way ANOVA with post-hoc Tukey analysis).